Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer

Ki Sung Ryu, Jae-Hoon Kim, Hyun Sun Ko, Jin Woo Kim, Woong Shick Ahn, Yong Gyu Park, Seung Jo Kim, Joon Mo Lee

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carboplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitoneal temperature at 43-44°C during surgery. Results. The overall 5-year survival rate was 58.6%; that of the IPHC group was 63.4% vs. 52.8% in the control group, with significantly higher survival in the IPHC group (P = 0.0078). Considering stage III ovarian cancer patients only (n = 74), the survival rate was 53.8% in the IPHC group (n = 35) and 33.3% in the control group (n = 39) and was significantly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), the 5-year survival rate was 65.6% in patients who underwent IPHC (n = 26) and 40.7% in the control patients (n = 27) (P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.

Original languageEnglish
Pages (from-to)325-332
Number of pages8
JournalGynecologic Oncology
Volume94
Issue number2
DOIs
Publication statusPublished - 2004 Jan 1

Fingerprint

Ovarian Neoplasms
Drug Therapy
Survival Rate
Control Groups
Neoplasm Staging
Carboplatin
Gynecology
Interferons
Therapeutics
Multivariate Analysis
Temperature
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Ryu, K. S., Kim, J-H., Ko, H. S., Kim, J. W., Ahn, W. S., Park, Y. G., ... Lee, J. M. (2004). Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecologic Oncology, 94(2), 325-332. https://doi.org/10.1016/j.ygyno.2004.05.044
Ryu, Ki Sung ; Kim, Jae-Hoon ; Ko, Hyun Sun ; Kim, Jin Woo ; Ahn, Woong Shick ; Park, Yong Gyu ; Kim, Seung Jo ; Lee, Joon Mo. / Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. In: Gynecologic Oncology. 2004 ; Vol. 94, No. 2. pp. 325-332.
@article{51d6f0d6178e4089b65e9eb7498de7fb,
title = "Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer",
abstract = "Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carboplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitoneal temperature at 43-44°C during surgery. Results. The overall 5-year survival rate was 58.6{\%}; that of the IPHC group was 63.4{\%} vs. 52.8{\%} in the control group, with significantly higher survival in the IPHC group (P = 0.0078). Considering stage III ovarian cancer patients only (n = 74), the survival rate was 53.8{\%} in the IPHC group (n = 35) and 33.3{\%} in the control group (n = 39) and was significantly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), the 5-year survival rate was 65.6{\%} in patients who underwent IPHC (n = 26) and 40.7{\%} in the control patients (n = 27) (P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.",
author = "Ryu, {Ki Sung} and Jae-Hoon Kim and Ko, {Hyun Sun} and Kim, {Jin Woo} and Ahn, {Woong Shick} and Park, {Yong Gyu} and Kim, {Seung Jo} and Lee, {Joon Mo}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2004.05.044",
language = "English",
volume = "94",
pages = "325--332",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Ryu, KS, Kim, J-H, Ko, HS, Kim, JW, Ahn, WS, Park, YG, Kim, SJ & Lee, JM 2004, 'Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer', Gynecologic Oncology, vol. 94, no. 2, pp. 325-332. https://doi.org/10.1016/j.ygyno.2004.05.044

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. / Ryu, Ki Sung; Kim, Jae-Hoon; Ko, Hyun Sun; Kim, Jin Woo; Ahn, Woong Shick; Park, Yong Gyu; Kim, Seung Jo; Lee, Joon Mo.

In: Gynecologic Oncology, Vol. 94, No. 2, 01.01.2004, p. 325-332.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer

AU - Ryu, Ki Sung

AU - Kim, Jae-Hoon

AU - Ko, Hyun Sun

AU - Kim, Jin Woo

AU - Ahn, Woong Shick

AU - Park, Yong Gyu

AU - Kim, Seung Jo

AU - Lee, Joon Mo

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carboplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitoneal temperature at 43-44°C during surgery. Results. The overall 5-year survival rate was 58.6%; that of the IPHC group was 63.4% vs. 52.8% in the control group, with significantly higher survival in the IPHC group (P = 0.0078). Considering stage III ovarian cancer patients only (n = 74), the survival rate was 53.8% in the IPHC group (n = 35) and 33.3% in the control group (n = 39) and was significantly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), the 5-year survival rate was 65.6% in patients who underwent IPHC (n = 26) and 40.7% in the control patients (n = 27) (P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.

AB - Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carboplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitoneal temperature at 43-44°C during surgery. Results. The overall 5-year survival rate was 58.6%; that of the IPHC group was 63.4% vs. 52.8% in the control group, with significantly higher survival in the IPHC group (P = 0.0078). Considering stage III ovarian cancer patients only (n = 74), the survival rate was 53.8% in the IPHC group (n = 35) and 33.3% in the control group (n = 39) and was significantly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), the 5-year survival rate was 65.6% in patients who underwent IPHC (n = 26) and 40.7% in the control patients (n = 27) (P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=3543129479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543129479&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.05.044

DO - 10.1016/j.ygyno.2004.05.044

M3 - Article

VL - 94

SP - 325

EP - 332

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -